基线瘤体大小作为预后指标在接受实验性靶向药物治疗的晚期实体肿瘤患者中的研究。 (Note: This translation assumes that "Baseline Tumor Size" is a term in the field of medicine that refers to the initial size of a tumor before treatment. If this is not the case, please provide more context for a more accurate translation.)
Baseline Tumor Size as Prognostic Index in Patients With Advanced Solid Tumors Receiving Experimental Targeted Agents.
发表日期：2023 Aug 07
作者：
Eleonora Nicolò, Paolo Tarantino, Oriana D'Ecclesiis, Gabriele Antonarelli, Luca Boscolo Bielo, Antonio Marra, Sara Gandini, Edoardo Crimini, Federica Giugliano, Paola Zagami, Chiara Corti, Dario Trapani, Stefania Morganti, Carmen Criscitiello, Marzia Locatelli, Carmen Belli, Angela Esposito, Ida Minchella, Massimo Cristofanilli, Sara M Tolaney, Giuseppe Curigliano
来源：
Experimental Hematology & Oncology
摘要：
基线肿瘤大小（BTS）与接受免疫治疗的癌症患者的预后有关。然而，BTS对接受靶向治疗（TTs）的患者的预后影响尚未确定。我们回顾了我院在2014年1月至2021年4月期间连续治疗的晚期实体肿瘤患者的数据，并进行了分类处理，根据治疗方式分为基于免疫疗法或基于TT的治疗（基于生物标记和非基于生物标记）。BTS是根据RECIST1.1基线目标病灶的总和计算的。共有444名患者符合条件，中位数BTS为69毫米（IQR，40-100）。BTS低于中位数的患者的总生存期（OS）显著长于BTS高于中位数的患者（16.6 vs 8.2个月，P <0.001），甚至在接受免疫治疗的患者中也是如此（12 vs 7.5个月，P = 0.005）。在接受TT的患者中，较低的BTS与较长的进展生存期（PFS）（4.7 vs 3.1个月，P = 0.002）和总生存期（OS）（20.5 vs 9.9个月，P <0.001）相关联，而高BTS却相反。然而，在接受生物标记匹配的TT的患者中，这种关联仅在低BTS亚组中显著，PFS和OS较长（PFS：6.2 vs 3.3个月，P <0.001；OS：21.2 vs 6.7个月，P <0.001），尽管ORR相似（28% vs 22%，P = 0.57）。在接受不匹配的TT的患者中，BTS与PFS（3.7 vs 4.4个月，P = 0.30），OS（19.3 vs 11.8个月，P = 0.20）和ORR（33% vs 28%，P = 0.78）相似，没有与预后相关性。多变量分析证实BTS独立与PFS（P = 0.03）和OS（P <0.001）相关，但与ORR无关（P = 0.11）。较高的BTS与接受基于生物标记匹配的TT的患者较差的生存预后相关。© 作者2023。由牛津大学出版。
Baseline tumor size (BTS) has been associated with outcomes in patients with cancer treated with immunotherapy. However, the prognostic impact of BTS on patients receiving targeted therapies (TTs) remains undetermined.We reviewed data of patients with advanced solid tumors consecutively treated within early-phase clinical trials at our institution from 01/2014 to 04/2021. Treatments were categorized as immunotherapy-based or TT-based (biomarker-matched or not). BTS was calculated as the sum of RECIST1.1 baseline target lesions.A total of 444 patients were eligible; the median BTS was 69 mm (IQR 40-100). OS was significantly longer for patients with BTS lower versus higher than the median (16.6 vs. 8.2 months, P < .001), including among those receiving immunotherapy (12 vs. 7.5 months, P = .005). Among patients receiving TT, lower BTS was associated with longer PFS (4.7 vs. 3.1 months, P = .002) and OS (20.5 vs. 9.9 months, P < .001) as compared to high BTS. However, such association was only significant among patients receiving biomarker-matched TT, with longer PFS (6.2 vs. 3.3 months, P < .001) and OS (21.2 vs. 6.7 months, P < .001) in the low-BTS subgroup, despite a similar ORR (28% vs. 22%, P = .57). BTS was not prognostic among patients receiving unmatched TT, with similar PFS (3.7 vs. 4.4 months, P = .30), OS (19.3 vs. 11.8 months, P = .20), and ORR (33% vs. 28%, P = .78) in the 2 BTS groups. Multivariate analysis confirmed that BTS was independently associated with PFS (P = .03) and OS (P < .001) but not with ORR (P = .11).Higher BTS is associated with worse survival outcomes among patients receiving biomarker-matched, but not biomarker-unmatched TT.© The Author(s) 2023. Published by Oxford University Press.